Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 25, 2017. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It contains only transaction-specific data:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $41.1461 per share.
- Transaction Volume: 28.716 shares.
- Transaction Date: April 25, 2017.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of ordinary shares by a Principal Director or Manager (PDMR) following the re-investment of dividends paid on April 13, 2017, under the Deferred Annual Bonus Plan Post-Tax matching award.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a single transaction.
Key Facts for Investor Verification
- Verify the identity of the insider: Mr. B McNamara, CEO of Consumer Healthcare.
- Confirm the nature of the transaction: Acquisition of shares via dividend re-investment, not an open-market purchase.
- Note the transaction volume is minimal (28.716 shares), indicating a routine plan-based transaction rather than a significant change in ownership.
- Recognize that this filing does not contain quarterly or annual financial performance data.